An estimation of burden of serious fungal infections in France
Jean‐Pierre Gangneux(Inserm), B. Dupont(Délégation Paris 5), C. Godet(Centre Hospitalier Universitaire de Poitiers), M.-E. Bougnoux(Hôpital Necker-Enfants Malades), J. Chandenier(Centre Hospitalier Universitaire de Tours), David W. Denning(Manchester Academic Health Science Centre), Christophe Hennequin(Inserm)
Cited by 93
Related Papers
Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group
|Clinical Infectious Diseases|2008|4.9k
Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis
|New England Journal of Medicine|2002|3.3k
Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision
|Journal of Fungi|2017|2.9k
Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America
|Clinical Infectious Diseases|2016|2.8k
Treatment of Aspergillosis: Clinical Practice Guidelines of the Infectious Diseases Society of America
|Clinical Infectious Diseases|2008|2.7k